ArticleFrontiers in neuroscience2026
Attention-enhanced segmentation network for automated cerebral microbleed detection and burden assessment.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Accuracy of Deep Learning in Detecting Cerebral Microbleeds: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cerebral microbleeds (CMBs) are small hemorrhagic lesions visible as hypointense foci on susceptibility-sensitive MRI and are established biomarkers of stroke risk and amyloid-related imaging abnormalities (ARIA-H) in patients receiving anti-amyloid therapy. However, automated detection remains challenging because true CMBs closely resemble veins, calcifications, and susceptibility artifacts. This visual ambiguity results in a persistent precision-recall trade-off, where models optimized for high sensitivity tend to generate excessive false positives, while precision-focused models risk missing clinically relevant lesions. To address this limitation, we propose an attention-enhanced segmentation framework designed to suppress confounding activations while preserving lesion sensitivity. Methods: We developed RLK-UNet with Convolutional Block Attention Modules (CBAM), a single-stage encoder-decoder architecture that redefines skip connections as context-filtered pathways. The encoder incorporates large 13×13 residual local kernel (RLK) convolutions to capture broad contextual information for distinguishing spherical microbleeds from elongated vascular structures. CBAM modules are embedded in all skip connections to selectively enhance lesion-relevant features and suppress irrelevant background responses before feature fusion. The model was trained and evaluated on a multi-site dataset of 506 T2*-GRE and SWI scans, with lesion-level detection assessed using precision, recall, F1-score, and average false positives per scan. Subject-level burden estimation was further evaluated using ARIA-H severity intervals. Results: The proposed model achieved state-of-the-art lesion-level performance, with a precision of 0.891, recall of 0.887, F1-score of 0.887, and a markedly reduced false positive rate of 0.83 per subject. Five-fold cross-validation demonstrated stable performance with minimal variance across splits. In lesions ≤3 mm, the model maintained strong detection performance (F1-score 0.869) while effectively controlling false positives. Cross-modality evaluation between T2*-GRE and SWI confirmed robust generalization. Ablation studies verified that CBAM significantly improved precision while preserving sensitivity, and Grad-CAM visualizations demonstrated more spatially focused and clinically interpretable attention patterns. Subject-level CMB counts strongly correlated with ground truth (Spearman Conclusion: RLK-UNet with CBAM provides a robust and interpretable solution for automated CMB detection by directly addressing false-positive propagation through attention-guided skip connections. The framework achieves balanced precision and sensitivity within a single-stage architecture and demonstrates reliable subject-level burden estimation aligned with clinically meaningful ARIA-H categories. These findings support its potential application in vascular risk stratification and treatment monitoring in patients undergoing anti-amyloid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.